Introduction

Acetylcholine is a familiar neurotransmitter with many different roles. Anticholinergics (AChs) are substances that antagonize the actions of the neurotransmitter acetylcholine at the muscarinic receptors. More than 600 compounds with ACh activity have been identified, and there were nearly 14,000 exposures to these substances in 2015. AChs can be employed for a variety of different medical conditions, including urinary incontinence, chronic obstructive pulmonary disease, motion sickness, cholinergic toxicity, and Parkinson's disease, just to name a few. ACh toxicity is encountered relatively frequently in the emergency department, so it is important that emergency providers promptly and efficiently recognize the toxidrome. This review will cover the pathophysiology, presentation, and management of anticholinergic toxicity. Children and adults have very similar presentations and management, with the only difference being that in children the most common cause is unintentional ingestions. Teenagers and young adults may ingest certain compounds for hallucinogenic properties (like jimson weed) or suicide.

Pathophysiology

Muscarinic receptors are present on the target organ cells of the parasympathetic nervous system and sweat glands in the sympathetic nervous system. In an overdose, AChs antagonize muscarinic receptors, which can lead to the following clinical manifestations:

- General: hyperthermia
- Cardiovascular: tachycardia, flushing, and dysrhythmias
- Gastrointestinal: decreased gut motility, constipation, vomiting, decreased saliva and tear production
- Genitourinary: urinary retention
- HEENT: blurry vision, mydriasis, narrow-angle glaucoma, potential vision loss
- Skin: Dry skin through the inhibition of sweating
- Musculoskeletal: diminished muscle contraction

The useful memory aid "red as a beet, dry as a bone, blind as a bat, mad as a hatter, hot as a hare, and full as a flask" helps to remember the common signs and symptoms of ACh toxicity. The adverse effects of AChs can be divided into central and peripheral effects.

Central effects result from excess blockade of muscarinic receptors within the CNS. Peripheral adverse effects result from the antagonism of exocrine glandular secretion, muscle contraction, and end-organ targets of the peripheral parasympathetic nervous system. The onset of ACh toxicity varies depending on the toxin but typically begins within one to two hours of oral ingestion.

Presentation

ACh toxicity is characterized as peripheral, central, or both. While peripheral signs alone are less concerning, the presence of central findings is consistent with a more severe clinical picture. Central effects often develop together with peripheral effects but may persist longer or appear after peripheral effects resolve. Patients with central CNS toxicity require longer observation and more aggressive care. Decreased or absent bowel sounds and tachycardia are the first indications of acute ACh toxicity.

<table>
<thead>
<tr>
<th>Memory Aid</th>
<th>Mechanism</th>
<th>Clinical Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mad as a hatter</td>
<td>Blockade of CNS muscarinic receptors Indicates “severe” ACh poisoning</td>
<td>CNS toxic effects: confusion, dysarthria, agitation, anxiety, hallucinations, delirium, seizures, coma.</td>
</tr>
<tr>
<td>Dry as a bone</td>
<td>Sweat glands are innervated by muscarinic receptors, ACh blockade leads to decreased sweat production</td>
<td>Dry skin</td>
</tr>
<tr>
<td>Red as a beet</td>
<td>The body tries to dispel heat by shunting blood flow to the skin to offset the loss of sweating</td>
<td>Flushed skin</td>
</tr>
<tr>
<td>Hot as a hare</td>
<td>Abnormal heat dissipation</td>
<td>Hyperthermia</td>
</tr>
<tr>
<td>Blind as a bat</td>
<td>Muscarinic effects in the eye contribute to pupillary constriction and accommodation, and AChs inhibit these actions leading to mydriasis and ineffective accommodation</td>
<td>Blurry vision</td>
</tr>
<tr>
<td>Full as a flask</td>
<td>Muscarinic receptors control the detrusor muscle of the bladder and urethral sphincter; consequently, AChs reduce detrusor contraction and prevent urethral sphincter opening</td>
<td>Urinary retention</td>
</tr>
</tbody>
</table>

In addition, you need to recognize chronic ACh toxicity. Patients treated with multiple medications that possess ACh effects may present with more elusive symptoms consistent with ACh toxicity, like altered mental status. These patients may not present with all the traditional signs and symptoms of ACh toxicity, and their presentation may be wrongly attributed to a different diagnosis. It is important for you to be aware of the classes of medications with ACh properties.
ACh poisoning should be considered in all patients presenting with an altered mental status and physical exam findings consistent with ACh toxicity. The diagnosis of ACh toxicity is principally based on the physical exam and common clinical manifestations. Serum drug levels of AChs are not typically available and do not result in a reasonable amount of time to help with diagnosis.8

As usual, a general toxicologic workup should occur in the ED, which includes asking EMS or family members about other home medications, as well as other prescription medications found in the household. Make sure to ask about the following: specific agent, amount ingested, time of ingestion, and any potential co-ingestion. Law enforcement may need to be utilized to go to the patient’s place of residence to acquire the medication bottles if the patient is incapacitated or not being straightforward. Calling the patient’s pharmacy or any helpful EMR retrieving tricks may be beneficial.

Don’t just order the “tox workup,” as your attending might drop dead on the spot. On a basic level, some common toxicologic tests to order include salicylate and acetylamophen levels, fingerstick glucose, a CBC, a CMP to evaluate liver function, pregnancy test in women of childbearing age. Obtain an EKG to look for prolonged QRS interval, prolonged QTc interval, and possible arrhythmia. A serum creatine kinase may be ordered if rhabdomyolysis is suspected (e.g. patients with psychomotor symptoms or seizures). Doxylamine, an over-the-counter antihistamine sleep aid, has been associated with rhabdomyolysis.9

Any chemical compound or medical condition that yields a seizure, tachycardia, urinary retention, or an alteration in mental status should be included in the differential diagnosis. Many medications and diseases can cause agitated delirium. Infection should always be considered, such as meningitis, encephalitis, or sepsis. The onset of altered mental status may help. Delirium from ACh toxicity usually has a more sudden onset compared to other causes. Symptomimetic toxicity, salicylate overdose, and serotonin syndrome all cause tachycardia and hyperthermia, but only ACh toxicity has an absence of diaphoresis.

Decontamination
The majority of ACh toxicity is from oral ingestion, with a minority from cutaneous and ocular absorption.10 Depending on the route and timing of exposure, GI decontamination may be performed with activated charcoal. If the patient’s mental status is intact and ingestion of an ACh agent is likely, 1g/kg (maximum of 50 g) of activated charcoal should be given. Patients who refuse to swallow charcoal or cannot tolerate its administration should not be intubated solely for the purpose of charcoal administration. External decontamination may be required for topical agents.

Management
Management of any poisoned patient begins with stabilization of the airway, breathing, and circulation. Cardiac monitoring and pulse oximetry should be continued until cardiac and CNS symptoms completely resolve. A medical toxicologist should be involved as patients have better outcomes.

Sinus tachycardia is common, but typically resolves on its own. Do not jump to giving beta-blockers or other rate-altering agents. Prolonged QRS intervals and wide complex tachyarrhythmias may occur. Sodium bicarbonate has a role here, and much like TCA overdoses, can improve EKG findings and cardiotoxicity. See our handout on TCA overdose for more information on sodium bicarbonate therapy here.11

Remember to not forget about the patient’s bladder! Use POCUS to look for urinary retention, and intermittent versus indwelling catheterization might be required to relieve urinary retention.

Agitation and seizures should be treated with benzodiazepines (lorazepam 1 to 2 mg IV [pediatric dose: 0.1 mg/kg up to 2 mg maximum single dose]). Phenothiazines and butyrophenones are anticholinergic themselves. They should be avoided in most toxidrome syndromes. They are the wrong answers on test questions and clinical practice. Hyperthermia may be treated with evaporative cooling methods as needed.

Supportive care is adequate for the majority of cases. However, physostigmine should be considered in patients with moderate to severe delirium. Physostigmine is an acetylcholinesterase inhibitor that reversibly inhibits the enzyme acetylcholinesterase in both the CNS and peripheral nervous system.12 This increases the concentration of acetylcholine at the muscarinic receptors to overcome the ACh blockade. Physostigmine is controversial, as cholinerenic toxicity occurs if the patient does not actually have ACh toxicity or if the drug is inappropriately given.13 Two retrospective studies and one randomized trial in children suggest that the management of known or suspected isolated ACh poisoning with physostigmine appears to be safe with few complications.14

In short, talking with a toxicologist or poison center is highly recommended prior to administration. Atropine and resuscitative equipment should be available at the bedside and given if there are any signs of cholinerenic symptoms. The adult dose is 0.5 to 2 mg (0.02 mg/kg IV up to a max of 0.5 mg per dose in pediatric patients) given via slow IV push over 5 minutes. Additionally, smaller doses may be repeated after 20 to 30 minutes if agitated delirium occurs. Physostigmine should NEVER be given if a condition other than purely ACh poisoning is suspected (such as a tricyclic antidepressant overdose, see our handout on that here).

Disposition
Asymptomatic patients presenting with recent ingestion of an ACh substance should receive GI decontamination with activated charcoal and should be observed in the emergency room for at least 6 hours. If the patient remains asymptomatic, they can be discharged. Patients with mild ACh toxicity should be treated with activated charcoal and benzodiazepines if needed and observed for symptom resolution. If symptoms resolve within 6 hours, they may be discharged; if not, they should be admitted and observed. Patients suffering from severe ACh poisoning and those treated with physostigmine should be admitted to the intensive care unit for closer observation.
References